Latest News about Pharma/Biotech
Recent news which mentions Pharma/Biotech
From TalkMarkets
Tickers
GHRS
From TalkMarkets
An Aggressive ETF Portfolio For 2023
March 05, 2023
From TalkMarkets
Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million
March 04, 2023
Tickers
MRK
From TalkMarkets
Tickers
ALKS
From TalkMarkets
Tickers
SPRC
From TalkMarkets
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio By 2-To-1 Margin YTD
February 26, 2023
From TalkMarkets
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
February 26, 2023
From TalkMarkets
Recent Stock Purchase/Sale February 2023
February 26, 2023
From TalkMarkets
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
From TalkMarkets
Only 2 Of 5 Cannabis Categories Have Advanced YTD
February 25, 2023
From TalkMarkets
ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders
February 20, 2023
Tickers
ZYNE
From TalkMarkets
Novo Nordisk: Impulsive Sequence Favors Upside & Remain Supported
February 19, 2023
Tickers
NVO
From TalkMarkets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
From TalkMarkets
6 Largest Psychedelic Stocks Showing Strength; Up 11.5% YTD
February 17, 2023
From TalkMarkets
AMGN Near Buy Point With Strong Fundamentals And Rising Dividend
February 16, 2023
Tickers
AMGN
From TalkMarkets
Tuesday Talk: My Sweet CPI
February 14, 2023
From TalkMarkets
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
From TalkMarkets
From TalkMarkets
"Rags-To-Riches" Portfolio Down 8% Last Week
February 13, 2023
From TalkMarkets
"Multi-Bagger" Portfolio Update
February 12, 2023
From TalkMarkets
Top CRISPR Stocks
February 11, 2023
From TalkMarkets
Major Psychedelic Compound-Based Stocks UP 13% YTD
February 11, 2023
From TalkMarkets
From TalkMarkets
Thoughts For Thursday: Risk-Off, Risk-On
February 09, 2023
From TalkMarkets
Tickers
BCTX
From TalkMarkets
NeurAxis: Should You Buy This IPO?
February 08, 2023
From TalkMarkets
From TalkMarkets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
February 06, 2023
From TalkMarkets
How The 5 Cannabis Categories Performanced Last Week
February 05, 2023
From TalkMarkets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.